Anthrax vaccine adsorbed; human reactogenecity and immunogenecity trial to address change in route of administration and dose reduction

Trial Profile

Anthrax vaccine adsorbed; human reactogenecity and immunogenecity trial to address change in route of administration and dose reduction

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Apr 2014

At a glance

  • Drugs Anthrax vaccine (Primary)
  • Indications Anthrax
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Acronyms ADA
  • Most Recent Events

    • 16 Jul 2012 Quality of life results published in Vaccine.
    • 13 Sep 2009 Results were presented at ICAAC 2009.
    • 20 Dec 2008 Centers for Disease Control and Prevention will complete further data analysis in 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top